Almirall, S.A.

ALM

ES0157097017

Pharmaceuticals

Market Closed - BME Other stock markets 11:35:22 2024-05-15 am EDT			After market 02:16:21 pm
9.38 ^EUR	+1.96%		9.38	0.00%

May. 13	Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...
May. 13	Almirall confirms full-year targets despite higher first-quarter costs	RE

Almirall, S.A. Announces Resignation of Peter Guenter as Chief Executive Officer at the End of the Year

November 09, 2020 at 02:01 am EST

Almirall, S.A. announced that Peter Guenter, the Chief Executive Officer will leave the company at the end of the year.

Latest news about Almirall, S.A.

Global markets live: Pfizer, Chevron, Amazon, Booking, Apple, Novavax, SoftBank...	May. 13
Almirall confirms full-year targets despite higher first-quarter costs	May. 13	RE
Almirall: share price rises after 'solid' start to the year	May. 13	CF
European shares listless as investors brace for inflation test	May. 13	RE
Transcript : Almirall, S.A., Q1 2024 Earnings Call, May 13, 2024	May. 13
Almirall, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 12	CI
Almirall Signs License Deal with Eloxx Pharmaceuticals for Skin Diseases Treatment	Mar. 13	MT
Global markets live: Apple, Nintendo, Super Micro Computer, Currys, ABB...	Feb. 19
Almirall: share price surges after agreement with Novo Nordisk	Feb. 19	CF
Transcript : Almirall, S.A., 2023 Earnings Call, Feb 19, 2024	Feb. 19
Almirall Secures Global Rights for Blocking Monoclonal Antibody Under Deal with Novo Nordisk	Feb. 19	MT
Almirall S.A. Enters into an Exclusive License Agreement with Novo Nordisk	Feb. 19	CI
Almirall, S.A. Provides Earnings Guidance for the Year 2024	Feb. 19	CI
Almirall, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 18	CI
Transcript : Almirall, S.A. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 09:00 AM	Jan. 09
Almirall S.A. Initiates First Phase I Clinical Study of ALM223, an Interleukin 2 Mutant Fusion Protein for Autoimmune Diseases	Dec. 21	CI
Almirall: messenger RNA alliance with Belgium's etherna	Dec. 12	CF
Almirall Collaborates with etherna on Development of Severe Skin Disease Therapies	Dec. 12	MT
Almirall and Etherna Enter into A Multi-Target Alliance to Develop mRNA-Based Therapies in Medical Dermatology	Dec. 12	CI
Certain Shares of Almirall, S.A. are subject to a Lock-Up Agreement Ending on 10-DEC-2023.	Dec. 09	CI
Almirall: share price rises, EU green light for eczema treatment	Nov. 17	CF
European Commission Approves Almirall’s Skin Disease Drug	Nov. 17	MT
Almirall, S.A. Receives European Commission Approval of EBGLYSS(R) (lebrikizumab) for Moderate to-Severe Atopic Dermatitis	Nov. 17	CI
Almirall Teams Up with Absci on AI-designed Dermatological Disease Treatments	Nov. 14	MT
Sector Update: Health Care Stocks Advance Premarket Tuesday	Nov. 14	MT

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Sector

Pharmaceuticals

Calendar

2024-07-21 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Almirall, S.A.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.2 EUR

Average target price

11.28 EUR

Spread / Average Target

+22.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALMIRALL, S.A.	+11.34%	2.08B
NOVO NORDISK A/S	+31.37%	588B
JOHNSON & JOHNSON	-2.81%	364B
MERCK & CO., INC.	+20.43%	326B
ABBVIE INC.	+5.38%	285B
ASTRAZENECA PLC	+14.83%	239B
NOVARTIS AG	+9.93%	210B
ROCHE HOLDING AG	-6.95%	200B
AMGEN INC.	+10.90%	167B
PFIZER, INC.	+0.14%	161B

Other Pharmaceuticals

Almirall, S.A.

Equities

ALM

ES0157097017

Pharmaceuticals

Almirall, S.A. Announces Resignation of Peter Guenter as Chief Executive Officer at the End of the Year

Latest news about Almirall, S.A.

Chart Almirall, S.A.

Company Profile

Income Statement Evolution

Ratings for Almirall, S.A.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals